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Nitric oxide (NO), is a ubiquitous, water soluble, free radical gas, which plays key role in various physiological as well
as pathological processes. Over past decades, NO has emerged as a molecule of interest in carcinogenesis and
tumor growth progression. However, there is considerable controversy and confusion in understanding its role in
cancer biology. It is said to have both tumoricidal as well as tumor promoting effects which depend on its timing,
location, and concentration. NO has been suggested to modulate different cancer-related events including
angiogenesis, apoptosis, cell cycle, invasion, and metastasis. On the other hand, it is also emerging as a potential
anti-oncogenic agent. Strategies for manipulating in vivo production and exogenous delivery of this molecule for
therapeutic gain are being investigated. However, further validation and experimental/clinical trials are required for
development of novel strategies based on NO for cancer treatment and prevention. This review discusses the range
of actions of NO in cancer by performing an online MEDLINE search using relevant search terms and a review of
the literature. Various mechanisms by which NO acts in different cancers such as breast, cervical, gastric,colorectal,
and head and neck cancers are addressed. It also offers an insight into the dichotomous nature of NO and
discusses its novel therapeutic applications for cancer prevention and treatment.
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Introduction
Nitric oxide (NO) is a short-lived, endogenously pro-
duced gas that acts as a signaling molecule in the body.
Ignarro et al. and Palmer et al. simultaneously identified
NO as the endothelium-derived relaxing factor in 1987
[1,2]. It is synthesized by nitric oxide synthase (NOS) en-
zymes; produced by mammalian cells at an appropriate
magnitude and tempo, it serves as a key signaling mol-
ecule in various physiological processes. On the other
hand, excessive and unregulated NO synthesis has been
implicated as causal or contributing to pathophysio-
logical conditions including cancer. Expression of NOS
has been detected in various cancers such as cervical,
breast, central nervous system, laryngeal, and head and
neck cancers [3-7]. NO has been suggested to modulate
different cancer-related events [8]. However, several lines
of research have indicated that NO may have dual effects
in cancer. At concentrations measurable in many* Correspondence: kordesheetal@yahoo.co.in
1Department of Oral Pathology & Microbiology, Yerala Dental College and
Hospital, Institutional Area, Sector 4, Kharghar, Navi Mumbai, Maharashtra 410
210, India
Full list of author information is available at the end of the article
© 2013 Korde Choudhari et al.; licensee BioMe
Creative Commons Attribution License (http:/
distribution, and reproduction in any mediumdifferent types of clinical samples, NO seems to promote
tumor growth and proliferation. In contrast to this, NO
is said to have tumoricidal effects;various direct and in-
direct mechanisms have been proposed for its antitumor
properties [9,10], although there is lack of data directly
on cancer patients. Nevertheless, the tumoricidal proper-
ties of NO are being investigated for therapeutic pur-
poses. NO is used alone or in combination with other
cytotoxic agents. In order to obtain a better insight into
the dichotomous nature of NO, an online search using
proper search terms through MEDLINE was undertaken
and the relevant literature was reviewed. This review dis-
cusses the diverse actions of NO in cancer and NO’s
novel applications in cancer treatment and prevention.Biological and physiological aspects of NO
NO, a short-lived endogenously produced gas, is synthe-
sized by a complex family of NOS enzymes. Mammalian
cells are endowed with three genes encoding distinct
isoforms of NOS– NOS1, NOS2, and NOS3 –with 51-
57% homology between isoforms and different localiza-
tions, regulation, catalytic properties, and inhibitor
sensitivity. NOS1, also known as nNOS (isoform firstd Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Diverse actions of NO in cancer: tumor
promoting role of NO
Tumor promoting role
Role of nitric oxide (NO) Mechanism by which NO acts
Genotoxicmechanisms Formation of toxic and mutagenic
species
Direct modification of DNA– strand
breaks, oxidation and deamination of
nucleic acids
Inhibition of systems required to repair
DNA lesions
Antiapoptotic effects GC to AT mutations in p53– loss of its
repressor activity
Direct inhibition of caspase activity
through s-nitrosylation of the cysteine
thiol
Inhibition of cytochrome C release
Increase in Bcl-2 expression




Dilatation of arteriolar vessels by eNOS
VEGF release and NO stimulation of
hyperpermeability of vascular
endothelium
Increased production of PGE2 resulting
in increased tumor vasculature
permeability
Activation of COX-2 which stimulates
production of proangiogenic factors
and prostaglandins
Limits host immune response
against tumor
Suppression of proliferation and
infiltration of leukocytes
Low leukocyte-endothelial interaction
Promotes metastasis Promotes lymphangiogenesis and
spread to lymph nodes possibly
through involvement of VEGF-C
Upregulation of MMP-2 and −9
Downregulation of TIMP-2 and-3
Korde Choudhari et al. World Journal of Surgical Oncology 2013, 11:118 Page 2 of 11
http://www.wjso.com/content/11/1/118purified and cloned from neuronal tissue), and NOS3 or
eNOS (isoform first found in endothelial cells) are also
termed as constitutive since they are expressed continu-
ously in neurons and endothelial cells, respectively. They
are also dependent on a rise in tissue calcium concentra-
tion for activity and therefore produce low, transient
concentrations of NO. In contrast, NOS2 is an inducible,
calcium-independent isoform, also called iNOS. Unlike
NOS1 and NOS3, induction of NOS2 results in continu-
ous production of NO [11]. It is inducible by immuno-
logical stimuli in virtually all nucleated mammalian cells.
Once induced, the enzyme continues to produce much
higher NO concentrations for many hours or even days.
An important regulator of NOS2 is the tumor suppres-
sor gene p53 which senses raised cellular NO and in-
hibits NOS2 by a negative feedback loop [12]. This
relationship has important implications in cancer.
Contrary to conventional biosignaling molecules that
act by binding to specific receptor molecules, NO mani-
fests its biological actions via a wide range of chemical
reactions. The precise reactions depend on the concen-
tration of NO achieved and on subtle variations in the
composition of intra- and extracellular milieu [11].
Under normal physiological conditions, cells produce
small but significant amounts of NO which contribute
to regulation of anti-inflammatory effects and its antioxi-
dant properties [13,14]. However, in tissues with a
high-output of NO, iNOSisupregulated and effects such
as nitration (addition of NO2), nitrosation (addition of
NO+), and oxidation will prevail [13]. Interaction of NO
with O2 or O2
- results in formation of reactive nitrogen
species (RNS). The RNS, dinitrogen trioxide (N2O3) and
peroxynitrite (ONOO), can induce two types of chemical
stresses,nitrosative and oxidative [15]. N2O3 is a potent
nitrosating agent which has been shown to N- and
S- nitrosate a variety of biological targets to yield poten-
tially carcinogenic nitrosamines and nitrosothiol deriva-
tives. N-nitrosation may have important implications in
the known association between chronic inflammation
and malignant transformation [15,16]. O2
- and NO may
rapidly interact to produce the potent cytotoxic oxidants
peroxynitrite (ONOO-) and its conjugate acid ONOOH.
Peroxynitrite in natural solution is a powerful oxidant,
oxidizing thiols or thioethers, nitrating tyrosine residues,
nitrating and oxidizing guanosine, degrading carbohy-
drates, initiating lipid peroxidation and cleaving DNA,
which has important implications in cancer [17,18].
Diverse actions of NO in cancer
NO has been reported to exert dichotomous effects
within the multistage model of cancer (Tables 1 and 2).
It modulates different cancer-related events including
angiogenesis, apoptosis, cell cycle, invasion, and metasta-
sis [8] (Table 1). In contrast to tumor promoting effects,NO has also been reported to have tumoricidal effects
(Table 2). Understanding its role in tumor biology will
help in reducing the controversy and confusion and will
help in developing novel NO based therapies which will
prove helpful in preventing and treating various human
cancers.
The effects of NO in tumor biology are broad, span-
ning its involvement in cellular transformation, forma-
tion of neoplastic lesions, and initiation and regulation
of the metastatic cascade. NO participates in genotoxic
events [19,20]. It may mediate DNA lesions by formation
of toxic and mutagenic species, by direct modification
of DNA, or by inhibition of DNA repair mechanisms
[21]. RNS can mediate DNA strand breaks and can also
yield different types of mutations in DNA [22,23]. NO
Table 2 Diverse actions of NO in cancer: tumoricidal role
of NO
Tumoricidal role
Role of NO Mechanism by which NO acts
Cytostatic and\or cytotoxic
effect on tumor cells
NO suppresses cellular respiration and
also shifts iron metabolism
Suppression of DNA synthesis
Proapoptotic modulator by activating
caspase family proteases, upregulation of
p53, alteration in expression of
apoptosis-associated proteins
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tations in p53 which may contribute to loss of its repres-
sor activity. NO directly inhibits activity of caspases
providing an efficient means to block apoptosis. Other
antiapoptotic effects of NO rely on NO/cGMP depen-
dent inhibition of cytochrome C release, increase in
Bcl-2 expression that controls the mitochondrial perme-
ability transition pore, induction of heat-shock protein
(Hsp) 70 and Hsp 32, suppression of ceramide gener-
ation [24], and activation of cyclooxygenase-2 [24,25].
NO plays an important role in tumor progression by
regulation of angiogenesis. Endogenous NO promotes
tumor blood flow via dilatation of arteriolar vessels. It
decreases leukocyte endothelial adhesive interactions
and increases vascular permeability [26]. Studies have
shown that VEGF released as a purified protein or
produced by tumor cells requires a functional NO/
cGMP pathway within the end compartment to promote
neovascular growth. Another mechanism by which
NO promotes angiogenesis is by activation of COX-2
which stimulates the production of proangiogenic
factors and prostaglandins. NO also has an invasion
stimulating effect which is mediated by upregulation of
MMP-2 and MMP-9 (matrix metalloproteinases), andFigure 1 Potential roles of NO in tumor growth.downregulation of TIMP-2 and possibly TIMP-3 (tissue
inhibitors of MMP) [27]. Studies have indicated that NO
limits leukocyte cell proliferation which has adverse con-
sequences on the antitumor response of the host [23]. In
this way NO may be involved in the growth and spread
of tumors (Figure 1).
NO in various human cancers
Nitric oxide seems to play diverse roles in various hu-
man cancers [3-7]. Understanding different actions of
NO in these cancers at the molecular level can help in
providing NO based diagnostic or prognostic markers
and also in devising potential strategies for prevention
and treatment of these cancers.
NO and breast cancer
Breast cancer is currently the most common cancer in
women worldwide, both in developed and developing
countries [28]. NOhas been investigatedregarding its
possible involvement in the promotion of breast carcin-
oma. Specific expression of NOS has been reported in
breast cancer tissues [29] and in breast carcinoma cell
lines [30]. Increased amounts of NO have been observed
in blood of breast cancer patients [31] and higher NOS
activity has been found in invasive breast tumors when
compared with benign or normal breast tissue [29]. Au-
thors have found a high rate of NOS in in situcarcinoma
[29]. Furthermore, NOS activity has been found to be
higher in advanced grades of breast carcinomas [31]. All
these findings suggest that NOS expression in breast
cancer may be an early event in carcinogenesis.
NO is reported to have several important effects in the
control of neoplasms. Jadeskiet al. suggested that the
presence of eNOS in breast apocrine metaplastic cells of
fibrocystic disease in the human may promote the pro-
gression of metaplastic epithelium into carcinoma [32].
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esis, which could explain the positive correlation be-
tween NO biosynthesis and grade of malignancy [31].
Nitrotyrosine, a biomarker of NO, was found to be cor-
related with VEGF-C expression and lymph node metas-
tasis in breast cancer suggesting the role of NO in
progression of breast carcinoma [33]. Switzer et al.
showed that NOS2 expression in human breast tumors
is functionally linked to poor patient survival [34].
NO and hormones in breast cancer
Unlike other types of cancer, tumors of the breast are
greatly influenced by steroid hormones. Recent findings
implicate NO pathway in some of their effects. Estrogen
and progesteronecan regulate NOS and, in turn, the NO
produced has profound consequences on tumor cell
homeostasis [30,35]. It has been found that estrogen
stimulates eNOS release in breast tissue [36] where it
acts as a free radical. eNOS expression has been found
to be strongly correlated with estrogen receptor expres-
sion in a human breast cancer cell line, suggesting free
radicals as possible causes of breast cancer [36]. Proges-
terone has been found to activate iNOS expression. It
has been suggested that the low levels of NO produced
by eNOS mediate the proliferative effect of estrogen
[37]. On the other hand, an increase in apoptosis in re-
sponse to progesterone could implicate high levels of
NO produced by induction of iNOS expression [37].
Thus an understanding of the mechanisms and interac-
tions of steroid hormones with the NO pathway could
lead to the development of new approaches and strat-
egies for the effective treatment of breast cancer.
NO and cervical cancer
Cervical cancer is the second most common cancer in
women worldwide, with >200,000 deaths annually [38].
Epidemiological studies have revealed a number of risk
factors, including smoking, multiparity, long-term use of
oral contraceptives, chronic inflammation, and other sexu-
ally transmitted infections (e.g., chlamydia trachomatis
and herpes simplex virus type 2) [39]. Interestingly, these
cofactors all increaseNO levels in the cervical microenvir-
onment [40-42]. Significantly higher levels of NO were ob-
served in serum of patients with cervical cancer as
compared to healthy controls [43,44]. Increased NO levels
and markers of NO-mediated mutagenesis have been ob-
served in the cervixes of women with cervical intra-
epithelial neoplasia [45,46]. All these findings suggest that
NO has potential mutagenic and carcinogenic activity in
cervical cancer.
Human papillomaviruses, NO and cervical cancer
Infections with any of the 15 types of human papilloma-
viruses (HPV) cause virtually all cases of cervical andother anogenital cancers [47]. According to Wei et al.,
NO acts as a molecular cofactor with HPV infection in
cervical carcinogenesis [48]. Wei et al. found that the
presence of HR-HPV is associated with an increased re-
lease of NO in the human uterine cervix [49] and that
physiological doses of NO could promote malignant pro-
gression of HPV-infected cells in vivo. According to
them, various epidemiologically defined cofactors for
cervical cancer increase NO levels in the cervical micro-
environment [48]. This increase in NO causes earlier
mRNA expression, decreased pRb and p53 levels, low
p53 activity, and apoptotic indices in HPV-infected cells
in the cervix, resulting in increased survival of mutant
cells leading to carcinogenesis [48].
NO and lung cancer
Tobacco smoke is the main cause for lung cancer
[50,51]. It leads to chronic airway inflammation with ac-
cumulation and activation of leukocytes which produce
high levels of ROS and NO [52]. It has been demon-
strated that NO, nitrite, and nitrotyrosine are increased
in patients with lung cancer [49]. Chen et al. found sig-
nificantly higher levels of iNOS/NO in lung cancer tis-
sues of smokers than that of non-smokers [53]. Strong
immunoreactivity for iNOS and eNOS was observed in
dysplastic lesions in the lung [54]. Certain hexavalent
chromium [Cr(VI)] compounds have been postulated to
play a significant role in pulmonary tumorigenesis.
Forbes et al.concluded that repetitive exposure to par-
ticulate chromate induces an inflammatory environment
in the lung, accompanied by enhanced NO production,
which may promote lung carcinogenesis [55].
NO may contribute to lung carcinogenesis by nitration of
proteins. NO and its metabolites interact with ROS to gen-
erate potent nitrating agents leading to 3-nitrotyrosine for-
mation in proteins [56,57], which is one of several chemical
modifications that occur during oxidative/nitrosative stress
[57,58]. At high levels, NO inactivates p53 [59] and p53 in-
activation by nitration could also contribute to carcinogen-
esis given that over 90% of lung tumors are with defective
p53 [52]. With broad effects on angiogenesis, glycolysis, p53
activity, antioxidant potential in the lung, and alteration of
cell growth pathways, NO may create a microenvironment
that promotestumorigenesis and/or promotes tumor hetero-
geneity leading to metastasis [52]. The prognosis of lung
cancer is still poor because of the absence of valid ap-
proaches to its early detection. Exhaled breath analysis and
exhaled NO measurements may provide useful assays in
predicting diagnosis and disease progression [60].
NO in gastric cancer
Despite advances in surgical treatment and chemother-
apy, gastric cancer remains a major global health bur-
den; various etiologic factors have been linked with the
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high salt intake are positively associated with this neo-
plastic process. Controversial associations have been
found with smoking or drinking habits [61]. The three
enzymatic sources of NO, nNOS, eNOS, and iNOS, have
been characterized in the gastrointestinal tract [62].
There is enhanced expression of iNOS and eNOS in hu-
man colorectal cancers [63]. Colon cancer tissue has also
been found to express NOS mRNA [64].
Gastric carcinogenesis (GC) is considered as a multi-
stage progressive process. The early indicator for GC
predisposition is abnormal hyperproliferation of gastric
epithelial cells, such as chronic atrophic gastritis (CAG),
dysplasia (DYS) and intestinal metaplasia (IM), which
have been considered as precancerous lesions of GC
[65,66]. In a study by Feng et al., when the lesions
progressed from normal to chronic superficial gastritis
(CSG),CAG, IM, DYS, and finally to GC, the positive
immunostaining rates for p53, iNOS, and VEGF were
found to be significantly increased [64]. The study dem-
onstrated that the positive immunostaining rates of
iNOS were correlated well with GC lymph node metas-
tasis. All these findings suggested a role of NO in the
initiation and progression of GC. NOS can also deami-
nate DNA and cause mutations of tumor suppressor
genes, and possibly other oncogenes, such as c-met, and
initiate genetic alterations of gastric cells leading to gas-
tric malignancy [23].
H.pylori, NO and gastric cancer
GC may be considered the result of interplay between
host genetic profile and environmental toxic agents [67].
The link between H. pylori infection and GC has been
demonstrated by epidemiological data and in experimen-
tal animal models [68-71]. Overproduction of NO via in-
ducible iNOS is suggested to be a significant pathogenic
factor in H. pylori-induced gastritis [72]. Exposure of
gastric epithelial cells to bacterium results in the gener-
ation of reactive oxygen species (ROS) and iNOS that, in
turn, may cause genetic alterations leading to GC in a
subset of subjects [67].
An increasing frequency of p53 abnormalities occurs
as the gastric mucosa progresses from gastritis, through
IM, DYS, and early to advanced invasive GC [73]. C to
T mutations in p53 are induced by NO [74,75] which
might have been produced during H. pylori infections.
Based on these facts, it can be said that H. pylori may
lead to GC through overproduction of NO, as one of the
mechanisms.
NO in brain tumors
NO influences a great variety of vital functions including
vascular tone and neurotransmission. NO emerges as an
important mediator of neurotoxicity in a variety ofdisorders of the central nervous system (CNS). nNOS
expression may act as a putative useful indicator of brain
tumor differentiation and malignancy [75]. Cobbs et al.
examined human brain tumors for three NOS isoforms
and NADPH diaphorase, a histochemical marker of
NOS activity in the brain. Data of their study suggested
that malignant central nervous system neoplasms ex-
press unexpectedly high levels of NOS and suggest that
NO production may be associated with pathophysio-
logical processes important to these tumors [76].
NO in head and neck cancer
Oral squamous cell carcinoma (OSCC) is the sixth most
common malignancy and a major cause of morbidity
and mortality [77]. The high incidence of oral cancer
and oral pre-cancer has been linked with habits of to-
bacco chewing and smoking [78,79]. It is reasonable to
assume that components of tobacco, as initiators of in-
flammatory response, could be responsible for the gener-
ation of ROS/RNS that may lead to lipid peroxidation,
enhanced NO products, and deranged antioxidant
defense system in tobacco users [80]. The damage to
genes sustained by elevated ROS/RNS could be one of
the mechanisms by which cancer arises in long-term to-
bacco abuse [80]. Raised levels of NO2 and NO3 were
noted in patients with oral pre-cancer [81,82] and in
healthy individuals with tobacco habit [80,81]. This indi-
cates potential of nitrosative injury in tobacco users and,
therefore, NO may have clinical relevance as a bio-
marker of inflammation and estimation of cancer risk in
pre-cancer patients or in healthy tobacco users.
Alcohol intake is related to an increased predisposition
to oral cancer [83]. Cooper and Magwere suggested that
stimulation of NO production by ethanol is likely to play
an important role in the etiology of some cancers, in-
cluding head and neck cancer, which preferentially rely
on NO signaling [84]. Taken together, these facts impli-
cate the role of NO in development of oral cancer. Very
few studies have evaluated the role of NO in oral pre-
cancer. Whether NO actually acts as a protumoral agent
at a concentration which is present in oral pre-cancer
needs further evaluation. Studies are required to know
the exact role of NO in oral pre-cancer which will be
helpful in intervening the cancer process.
HPV, NO and head and neck cancer
The steady increase in the incidence of oropharyngeal
cancers over the last four decades has been mainly at-
tributed to oral HPV infection, which has been accepted
as an etiological factor for a subset of head and neck
squamous cell carcinoma (HNSCC) [85-88]. HPV-
positive HNSCCs have a unique risk factor profile. These
tumors are more common in younger patients, have a
male predominance, and are often staged higher, yet
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to have used tobacco and alcohol excessively [89]. An as-
sociation between chronic inflammation such as through
HPV infection and oral cancer is biologically plausible. It
is known that chronic inflammation can lead to the pro-
duction of NO which in turn can mediate DNA damage.
Considering these facts, the role of NO in HPV associ-
ated head and neck cancer in patients without habits,
needs an evaluation.
Tumoricidal versus tumor promoting effect of NO
Although several reports have addressed the protu-
moraleffects of NO, as mentioned above, few have demon-
strated the contrasting role of NO in mediating tumor
regression [9,90,91]. It has been reported that NO derived
from macrophages, Kupffer cells, natural killer cells, and
endothelial cells participates in tumoricidal activity against
many types of tumors [90,92]. These studies suggest that
NO has a cytostatic and/or cytotoxic effect on tumor cells
(Table 2, Figure 1). Several molecular targets, such as
aconitase and ribonucleotidereductase, have been impli-
cated in the cytostatic/cytotoxicity effects mediated by
NO. NO has been proposed to cause suppression of DNA
synthesis through the salvage pathway [93]. Long standing
overproduction of NO acts as a proapoptotic modulator,
activating caspase family proteases through the re-
lease of mitochondrial cytochrome C into the cytosol,
upregulation of p53 expression, and alterations in the
expression of apoptosis-associated proteins including the
Bcl-2 family [24]. A high NO level has been proposed to
suppress metastasis [94]. Baritakiet al. have shown
that high levels of NO derived from the NO donor
DETA-NONOate inhibits epithelial-mesenchymal transi-
tion (EMT) and reverses both the mesenchymal pheno-
type and the invasive properties of human prostate
metastatic cells [95]. Findings of the study by Bonavida
et al. have also suggested that NO donors may prove to be
potential therapeutic agents in both reversal of drug resist-
ance and the inhibition of EMT and metastasis [96]. Al-
though these tumoricidal roles of NO have been
proposed, most experiments have been performed in vitro
[11,97] and such findings have not been reported in can-
cer patients. It has been suggested that NO concentrations
found in OSCC and other solid tumors are insufficient to
produce apoptosis [98] and other tumoricidal effect and
are likely to facilitate angiogenesis and tumor dissemin-
ation [99]. Further, whether NO has an inhibitory
or stimulatory effect on the cancer process initially de-
pends on the concentration of NO achieved and also on
other factors such as the type of cell exposed, the redox
state, final intracellular concentration, duration of expos-
ure, etc., in the tumor bed. Once the cancer has begun,
NO seems to play a protumoral role rather than
antitumoralone as the concentration required to causetumor cell cytotoxicity cannot be achieved by cancer cells
[100]. However, considering the cytostatic and/or cyto-
toxic effects of NO, strategies are being developed to ma-
nipulate NO levels in the tumor environment for
therapeutic gain.
NO as a novel cancer therapeutic
NO may exert a biphasic response, such that when NO
levels go beyond a critical concentration that would be
suitable for tumor growth and survival, growth arrest
and/or apoptotic pathways are initiated. These charac-
teristics of NO have been exploited therapeutically with
impressive effects in pre-clinical models of cancer to
slow tumor growth and to enhance the efficacy of both
chemotherapy and radiotherapy [101]. Researchers are
investigating various strategies for manipulating in vivo
production and exogenous delivery of this molecule,
includingiNOS gene therapy, iNOS induction, and ad-
ministration of NO donor drugs [94] for therapeutic
gain.
Transfer of NOS-encoding cDNA sequences into can-
cer cells for gene therapy purposes was thought to be
one of the mechanisms for delivery of NO. However, as
both retroviral and adenoviral vectors may be hazardous
to the host, cell-based approaches to overcome the prob-
lems associated with gene therapy [102] are being
sought. Further work into the precise mechanisms of
this process is required.
Alternative mechanisms for NO delivery would be the
use of NO releasing drugs or NO donors. These are cap-
able of causing sustained release of NO with a wide
range of half-lives, and with predictable estimated doses.
They can simultaneously exert a multitude of anticancer
activities including enhancement of apoptotic stimuli, in-
hibition of metastasis, inhibition of angiogenesis, and in-
hibition of hypoxia, depending on concentration of NO
donor and on the cancer type and stage [103].
Several promising findings strongly support the thera-
peutic application of NO donors in cancer treatment,
used alone or in combination with other subtoxic doses
of cytotoxic agents. NO donors have been shown to have
the dual function of both sensitizing tumor cells to
chemotherapy and immunotherapy and of being
involved in the regulation and inhibition of me-
tastasis [104]. NO donors belonging to the class of
diazeniumdiolates are promising as they have been
shown to be effective chemo- and radio-sensitizing
agents along with other attractive properties such as
long half-lives and target tissue specific delivery. The
role of nitro-glycerine as a chemo-sensitizing agent as
demonstrated by Yasuda et al. [105,106], promises a safe
and affordable alternative for the management of resist-
ant or metastatic tumors. According to Bonavida and
Baritaki [107], NO donors may be considered as novel
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ment of patients with refractory cancer and in the pre-
vention of the initiation of the metastatic cascade via
EMT.
However, the therapeutic application of NO donors
has been limited by potential systemic effects exerted
in vivo. These adverse effects include vasodilation lead-
ing to pronounced hypotension and accumulation of
toxic metabolites such as cyanide [108]. The need to
develop the ideal NO donor with maximal anti-
proliferative properties and minimal side effects has led
to the invention of NO-hybrids. NO-hybrids are provid-
ing a unique niche in the armamentarium of anticancer
agents. Combining NO to existing drugs affords an ad-
vantage of adding or potentiating the effects of NO to
the benefits of drugs like NSAIDs or statins. NO-drug
hybrids such as NO-NSAIDs demonstrate promise as
anti-cancer agents and are in clinical trials by NCI-
sponsored phase I randomized studies (i.e., NO-aspirin
in high-risk patients with colorectal cancers) [109].
The synthesis of molecules capable of releasing opti-
mal amounts of NO at the right time and the right place
poses a great challenge to pharmaceutical research. NO
donors can be incorporated into or chemically linked to
biopolymers, mimicking endogenous NO production at
a target site [110,111]. Nanomaterials are currently being
harnessed to load high amounts of NO; they are quite
stable, are sometimes photoactive, and possess demon-
strable biological activity. Their surfaces can also be
chemically modified and optimized for specific medical
applications. They may facilitate the development of sys-
tems for simultaneous therapeutic and diagnostic appli-
cations [112]. These nanoparticles can be prepared by
physiochemical, chemical, and mechanical methods
[113]. However, drug release from particles may vary
according to the polymer used or the drug encapsulated
[114]. Nanocarriers of NO make the agent more avail-
able to systemic circulation and can also enhance the
NO target [112].
A small number of reports have been published on
the topical delivery of NO using polymeric systems.
Kanayama et al. [115] reported that PEGylated polymer
micelles may be capable of delivering exogenous NO to
tumor cells in a photocontrolled manner, resulting in an
NO-mediated antitumor effect, which indicates the
promise of this polymeric system in NO-based tumor
therapy. Friedman et al. reported that therapeutic levels
of NO, in controlled and sustained manner, can be
achieved by using combination of glassy matrices and
hydrogels [116]. NO-releasing hydrogel/glass hybrid
nanoparticles are preferable to other NO-releasing
compounds as they depend only on rate of hydration
and not on chemical decomposition or enzymatic
catalysis [117]. [Ru(Terpy)(bdqi)NO](PF6)3, a NO donornitrosyl ruthenium complex, has been bound to lipid
nanocarriers for topical administration. This system
exhibited improved stability in the skin and NO release
by visible light irradiation, with potential applications in
the treatment of skin cancer [118]. Stevens et al.
engineered NO-releasing SiNPs for NO delivery to hu-
man ovarian cancer cells for their inhibition [119]. An-
other class of liposomes that can be successfully used as
nanocarriers are thermosensitive liposomes; they can be
employed in the storage, delivery, and active release of
NO in a heat-mediated manner [120]. These thermo-
sensitive liposomes containing NO may have applica-
tions in anticancer therapeutics as heat is generated in
tumor tissue [121].
Fluorescent nanocrystals, also known as quantum dots
(QDs) can be linked to NO-donor molecules. These can
specifically lead to effective treatment of large tumors by
photodynamic therapy [116-122]. In this case, the
nitrosyl compounds can generate, under light applica-
tion, ROS and NOS via QD excitation, enabling tumor
cell death [117-124]. The preliminary in vitro experi-
ments with neuroblastoma cells have demonstrated
that the combination of nano-delivery and chemother-
apy enhances antitumor activity of chemotherapeutics
[125]. Current nanotechnology-based systems are highly
promising but there are currently no commercially
available nano- or microcarriers for NO delivery. Giles
et al. have recently reported the development of
two photolabileNO-releasing prodrugs, tert-butyl S-
nitrosothiol and tert-dodecane S-nitrosothiol. They con-
firmed that irradiation induced highly significant
increase in cytotoxicity in A549 lung carcinoma cells by
these drugs. These prodrugs can be further explored to
have applications in chemical biology studies and
chemotherapy [126]. Thus NO appears to be a poten-
tially promising agent for the treatment of cancer and
prevention of metastatic cascade and therefore further
studies are required to clearly understand the complex
and wide-ranging roles of NO in order to facilitate its
therapeutic use.
Conclusion
NO is a relatively stable, free radical gas that readily dif-
fuses into cells and cell membranes where it reacts with
molecular targets. The precise reactions of NO depend
on the concentration of NO achieved and on subtle vari-
ations in the composition of the intra- and extracellular
milieu. NO seems to play a part in various stages of car-
cinogenesis from initiation to progression. Expression of
NOS have been detected in various human cancers. In
breast cancer both the development of primary tumor
and the process of metastasis seems to be influenced by
the presence and amount of NO. In cervical carcinogen-
esis it acts as a molecular cofactor with HPV infection.
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may provide useful assays in providing diagnosis and
disease progression in lung cancer. NO can initiate ge-
netic alterations of gastric cells leading to gastric malig-
nancy. Exposure of gastric epithelial cells to H. pylori
bacterium may result in the generation of ROS and
iNOS which in turn may cause genetic alterations lead-
ing to GC. Various studies have suggested a role of NO
in the development of head and neck cancer. Thus NO
seems to have an important part in the initiation,
growth, and metastasis of various cancers. However, it is
said to have a tumoricidal role as well. NO has been sug-
gested to have a cytostatic and/or cytotoxic effect on
tumor cells. However, this depends on various factors
and once the cancer begins, NO seems to play
protumoralrather than an antitumoral role. On the other
hand, the tumoricidal properties of NO are being uti-
lized in the treatment of cancer. NO can act as a novel
potential therapeutic agent in patients with refractory
cancer by sensitizing tumor cells to chemotherapy,
radiotherapy or immunotherapy. Nevertheless, further
validation and experimental/clinical trials are required to
develop NO based strategies for cancer prevention and
treatment.
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